339

References

1. Remington, Sicence and Practice of Pharmacy, Published by

Wolters Kluwer Health (India) Pvt, Ltd, New Delhi, Volume I,

2007,495.

2. Mithal B.M, Text book of forensic pharmacy, Vallabh

Prakashan, 2003, 73.

3. Foye, W.O., (ed.), “Principles of Medicinal Chemistry”, 3rd Edn,

Varghese Company, Bombay, India, 1989, 26.

4. Wolff, M.E., (ed.), “Berger‟s Medicinal Chemistry”, 4th Edn, Wiley

Interscience, New York, 1981, 1.

5. Doserge, R.F. (ed.), “Wilson and Gisvold‟s Textbook of Organic,

Medicinal & Pharmaceutical Chemistry”, 8th Edn, Lippincott

Co., 1982, 1.

6. Korolkovas, A., “Essentials of Medicinal Chemistry”, 2nd Edn,

Wiley Interscience, New York, 1988, 3.

7. Goodman, A., and Gilman, Rall, T.W., Nies, A.S., and Taylor, P.,

“Goodman and Gilman‟s The Pharmacological Basis of

Therapeutics”, 8th Edn, Pergamon Press, New York, 1990, 45-

48.

8. The Drugs & Cosmetics Act & Rules, Government of India

Publications, 1984.

340

9. Indian Pharmacopoeia, Ministry of Health & Family Welfare,

Government of India, New Delhi, 1996.

10. British Pharmacopoeia, Convention Inc., Rockville, 2002.

11. British Pharmacopoeia, Her Majesty‟s Stationary Office, London,

2002.

12. Reynolds, J.E.F., “Martindale – The Extra Pharmacopoeia”, 33rd

Edn, The Pharmaceutical Press, London, 2002.

13. Chatten, L.G., (Ed. By), “Pharmaceutical Chemistry”, Vol. I and

II, Marcel Dekker Inc., New York, 1996, 1-2.

14. Beckett, A.H., and Stenlake, J.B., “Practical Pharmaceutical

Chemistry”, Vol. I and II, CBS Publishers & Distributors, New

Delhi, 1986, 2-5.

15. Sethi, P.D., “Quantitative Analysis of Drugs in Pharmaceutical

Formulations”, 3rd Edn, New Delhi, 1986, 1-2.

16. Willard, H.H., Merrit, L.L. Jr., Dean, J.A., and Settle, F.A. Jr.,

“Instrumental methods of analysis”, 6th Edn., CBS Publishers,

New Delhi, India,Year,1-6.

17. Day, R.A., and Underwood, A.L., “Quantitative Analysis”, 4th

Edn, Prentice Hall, New Delhi, 1986, 2-4.

341

18. Basett, J., Denney, R.C., Jerrery, G.H., and Mendham, J.,

“Vogel‟s Textbook of quantitative Inorganic Analysis”, 4th Edn,

Longman Group, England, 1986, 1-6.

19. Macek, T., and Kareel, D., “Pharmaceutical applications of thin-

layer and paper chromatography”, Elsevier Publishing

Company, Amsterdam, 1972.

20. Ramana Rao, G., Murthy, S.S.N., and Khadgapathi, P., “Gas

chromatography to pharmaceutical analysis (Review)”, Eastern

Pharmacist, 30 (353), 1987, 35.

21. Ramana Rao, G., Murthy, S.S.N., and Khadgapathi, P., “High

performance liquid chromatography and its role in

pharmaceutical analysis (Review)”, Eastern Pharmacist, 29

(346), 1986, 53.

22. Sastry, C.S.P., Prasad, T.N.V., and Rao, E.V., “Recent

application of high performance liquid chromatography in

pharmaceutical analysis (Review)”, Indian J. Pharm. Education,

21, 1987, 37.

23. Cheronics, N.D., and Ma, T.S., “Organic functional group

analysis by micro and semimicro methods”, Interscience, New

York, 1964.

24. Higuchi, T., and Brochman-Hausen, E., Pharmaceutical

Analysis, Edn, Interscience, London, 1961.

342

25. Siggia, S., and Hanna, J.G., “Quantitative organic analysis via

functional groups”, 4th Edn, Wiley-Interscience, Nottingholm,

1979.

26. Remington, Sicence and Practice of Pharmacy, Published by

Wolters Kluwer Health (India) Pvt, Ltd, New Delhi, Volume I,

2007, 1556-1570.

27. Salmon, S. E. and Sartorelli, A. C. Cancer Chemotherapy, in

Basic and Clinical Pharmacology, (Katzung, B. G., Ed) Appleton-

Lange, 1998, 881-911.

28. Besthron, E., Ber. Otsch. Chem. Ges., 43, 1910, 1519.

29. Huning, S., and Fritsch, K.H., Ann. Chem., 609, 1957, 143 and

172.

30. Huning, S., Balli, H., Briether, E., Bruhne, F., Geiger, H.,

Grigat, E., Muller, F., and Quast, H., Angew. Ann.Chem, 74,

1962, 818.

31. Sawicki, E, Hauser, T.R., Stanley, T.W., and Elbert, W., Anal.

Chem., 33, 1961, 93.

32. Sawicki, E., Schumachar, R., and Engel, C.R., Microchem. J.,

12, 1967, 377.

33. Hauser, T.R., and Cummins, R.L., Anal. Chem., 36, 1964, 679.

34. Alshuller, A.P., and Leng, L.J., Anal. Chem., 35, 1963, 1541.

343

35. Kamata, E., Bull. Chem. Soc., Japan, 38, 1965, 2005.

36. George, J.N., Anal. Chem., 53, 1981, 1708.

37. Cohen, I.R., and Altshuller, A.P., Annal. Chem., 38, 1966, 1418.

38. Davis, R.P., and Janis, R., Nature, 210, 1966, 318.

39. Pays, M., Malargean, R., and Bourdon, R., Ann. Pharm. Fra.,

24, 1966, 763.

40. Soda, K., Yorifuji, T., Misono, H., and Moriguchi, M., Biochem.

J., 114, 1969, 629.

41. Newman, F.W., Anal. Chem., 47, 1969, 2077.

42. Umeda, M., Yakugaku Zasshi, 83, 1963, 951.

43. Kamata, E., Bull. Chem. Soc., Japan, 37, 1964, 1674.

44. Pays, M., and Boudon, R., Ann. Pharm. Fr., 20, 1968, 681.

45. Sastry, C.S.P., Sankar, D.G., Reddy, M.N., and Singh, N.R.P.,

Indian Drugs, 25, 1988, 130.

46. Friestad, H.O., Ott. D.E., Gunther, F.A., Anal Chem., 43, 1969,

1750.

47. Pays, M., and Baljean, M., Ann. Pharm. Fr., 28, 1970,153.

48. Sawicki, E., Hauser, T.R., Stanley, T.W., and Elbert, W., Anal.

Chem., 33, 1961, 93.

344

49. Sawicki, T.W., Stanely, Hauser, T.R., Elbert, W. and Noe, J.L.,

Anal. Chem., 33, 1961, 722.

50. Sastry, C.P.S., Tirupathi Rao, T., and Sailaja, A., Talanta, 38,

1991, 1057.

51. Pays, M., Bourdon, R., and Beljean, M., Anal. Chem. Acta., 47,

1969,101.

52. Sawicki, E., Hauser, T.R., Stanely, T.W., Elbert, W., and Fox,

F.T., Anal Chem., 33, 1961, 1574.

53. Fog, J., and Jellum, E., Nature, 195, 1962, 490.

54. Pays, M., Ann. Pharm. Fr., 25, 1967, 29.

55. Hurst, E.R., Saltine, M.J., Anal. Biochem, 115, 1981, 88.

56. Kommons, E., and Micheal, E., Arch. Pharm. Chem. Sci. Ed.,

10, 1982, 146.

57. Persey, M., and Baltos, J., Ann. Pharm. Fr., 28, 1970, 153.

58. Serbbort, W.S., Photogr. Sci., 17, 1969, 13.

59. Sastry, C.S.P. and Sastry, B.S, The Eastern Pharmacist, 29

(345), 1986, 31.

60. Wesp, E.F., and Brode, W.R., J. Am. Chem. Soc., 56, 1934,

1037.

61. Iami, K., Yamada, S., Kubata, H., and Sakamaki, J. Eur. Pat.

Appl., 17 (1964); Chem. Abstr., 94, 1981, 9932f.

345

62. Besada, A., Anal. Lett, 20, 1987, 427.

63. Chowdhary, K.P.R., and Rao, G.D., Indian Drugs, 34(5), 1997,

283.

64. Sastry, C.S.P., Sankar, D.G., Reddy, M.N., and Aruna, M.,

Indian J. Pharm. Sci., 50, 1988,178.

65. Tren, C.C., Anal. Chem., 33, 1961, 849.

66. Collins, P.F., Diehl, H., and Frederick Smith, G., Anal. Chem.,

31, 1959, 1862.

67. Raggi, M.A., Cavrini, A.M., Di Pietra, and Lacche, D., Pharm.

Acta. Hel, 63, 1988, 19.

68. Barta, L., Biochem. Z., 274, 1934, 212.

69. Berrenscheen, H.K., and Dreguss, M., Ibid, 3, 1931, 305.

70. Lappin, G.R., and Clark, L.C., Anal. Chem., 23, 1951,541.

71. Mathewson, W.C., J. Am. Chem. Soc., 42, 1920, 1277.

72. Matheissen, G., and Dahn, H., Z. Ger. Exp. Med., 113, 1944,

336.

73. Pool, M.F., and Klose, A.A., J. Am. Oil. Chem. Soc., 28, 1945,

215.

74. Kirk, G.F., Bright, Talanta, 13, 1966, 1.

75. Pattergill, M.D., and Sands, D.E., J. Chem. Educ., 58, 1979,

244.

346

76. Sandell, E.B., “Colorimetric determination of traces of metals”,

Interscience, New York, 1950.

77. Ayres, G.H., Anal. Chem., 21, 1949, 652.

78. Guide for the use of terms in reporting data, Anal. Chem., 54,

1982,157.

79. Massart, D.L., Vandeginste, B.G.M., Deming, S.N., Michotte, Y.,

and Kaufman, L., “Chemometrics: A Textbook”, Elsevier,

Amsterdam, 1988.

80. Indian Pharmacopoeia, Ministry of Health & Family Welfare,

Government of India, New Delhi, Volume 2,2007,1243.

81. Martindale, the Extra Pharmacopoeia, 31st Edition, Royal

Pharmaceutical Society, 1996, 580-81.

82. Yang X, Hu Z, Chan SY, Goh BC, Duan W, Chan E and Zhou S,

“Simultaneous determination of the lactone and carboxylate

forms of irinotecan (CPT-11) and its active metabolite SN-38 by

high-performance liquid chromatography: application to plasma

pharmacokinetic studies in the rat”, J Chromatogr B Analyt

Technol Biomed Life Sci., 821(2),2005,221-8.

83. Poujol S, Pinguet F, Malosse F, Astre C, Ychou M, Culine S and

Bressolle F, “Sensitive HPLC-fluorescence method for irinotecan

and four major metabolites in human plasma and saliva:

347

application to pharmacokinetic studies”, Clin Chem.,

49(11),2003,1900-8.

84. Jong FA De, Mathijssen RH, Bruijn P de, Loos WJ, Verweij J

and Sparreboom A, ”Determination of irinotecan (CPT-11) and

SN-38 in human whole blood and red blood cells by liquid

chromatography with fluorescence detection”, J Chromatogr B

Analyt Technol Biomed Life Sci, 795(2), 2003,383-8.

85. Schoemaker NE, Rosing H, Jansen S, Schellens JH and Beijnen

JH, “High-performance liquid chromatographic analysis of the

anticancer drug irinotecan (CPT-11) and its active metabolite

SN-38 in human plasma”,Ther Drug Monit,25(1), 2003,120-4.

86. Rivory LP and Robert J, “Identification and kinetics of a beta-g

glucuronide metabolite of SN-38 in human plasma after

administration of the camptothecin derivative irinotecan”, J

Chromatogr B Biomed Appl, 36 (2), 1995, 176-9.

348

87. Barilero I, Gandia D, Armand JP, Mathieu-Boue A, Re

M,Gouyette A and Chabot GG, “Simultaneous determination of

the camptothecin analogue CPT-11 and its active metabolite

SN-38 by high-performance liquid chromatography: application

to plasma pharmacokinetic studies in cancer patients”, J

Chromatogr, 575 (2),1992, 275-80.

88. Sastry C.S.P, Reddy B.S and Mangala D.S, Indian Drugs, 21,

1984,526.

89. Das Gupta V., Indian J.Pharm, 35, 1973, 77.

90. Shingbal D.M, Ibid, 35, 1973,160.

91. Kyoji T, Shoh M and Toru U, Talanta, 29, 1982,103.

92. Reddy B.S and Sastry C.S.P, J.Inst.Of Chemists, (India), 5,

1983, 69.

93. Sastry B.S, Rao E.V, Tummuru M.K and Sastry C.S.P, Indian

Drugs, 24, 1986,105.

94. Viswanadham N, Reddy M.N and Sastry C.S.P, Indian

J.Pharm.Sci, 45, 1983, 81.

95. Martindale, the Extra Pharmacopoeia, 31st Edition, Royal

Pharmaceutical Society, 1996, 545.

96. Budavari S.Eds, Merck Index,14th edition, Edited by Maryadele,

J.O.Neil, Merck Research lab, division of Merck & Co., NJ,

2006, monograph no.1200,1203.

349

97. Singh AK, Chaurasiya A, Jain GK, Awasthi A, Asati D, Mishra

G, Khar RK, Mukherjee R.,"High performance liquid

chromatography method for the pharmacokinetic study of

bicalutamide SMEDDS and suspension formulations after oral

administration to rats",Talanta,78(4-5),2009,1310-4

98. Nageswara Rao R, Narasa Raju A, Narsimha R, J Pharm Biomed

Anal,”Isolation and characterization of process related

impurities and degradation products of bicalutamide and

development of RP-HPLC method for impurity profile study”,

46(3), 2008,505-19.

99. Nageswara Rao R, Narasa Raju A, Nagaraju D,”An improved and

validated LC method for resolution of bicalutamide enantiomers

using amylose tris-(3,5-dimethylphenylcarbamate) as a chiral

stationary phase”,J Pharm Biomed Anal, 42(3),2006,347-53.

100. Török R, Bor A, Orosz G, Lukács F, Armstrong DW, Péter A.,

High-performance liquid chromatographic enantioseparation of

bicalutamide and its related compounds,J Chromatogr A.

,1098(1-2), 2005,75-81.

101. Sancheti P. P, Vyas V. M., Manali Shah, Poonam Karekar and

Pore Y. V.,"Spectrophotometric Estimation of Bicalutamide in

Tablets", Indian J. Pharm. Sci., 70 (6), 2008, 810-812.

350

102. Xu LX,Shen YX,Wang HY,Jiang JG, Xiao Y, "Spectrophotometric

determination of procaine hydrochloride in pharmaceutical

products using 1,2-naphthoquinone-4-sulfonic acid as the

chromogenic reagent", Spectrochim Acta A Mol Biomol

Spectrosc,59(13),2003,3103-10.

104. Martindale, “The Complete Drug Reference”, Edited by Sean C

Sweetman, 34th Edition, 2005, p.557.

105. Farhan H, Wahala K, Cross HS,” Genistein inhibits vitamin D

hydroxylases CYP24 and CYP27B1 expression in prostate cells”,

J Steroid Biochem Mol Biol, 84(4), 2003,423-9.

106. Charles GD, Bartels MJ, Zacharewski TR, Gollapudi BB,

Freshour NL, Carney EW, “Activity of benzo[a]pyrene and its

hydroxylated metabolites in an estrogen receptor-alpha reporter

gene assay”, Toxicol Sci,55(2),2000, 320-6.

106. Zalcberg JR, Hu XF, Ching M, Wakeling A, Wall DM, Marschner

IC, Luise M de ,” Differential effects of estrogen, tamoxifen and

the pure antiestrogen ICI 182,780 in human drug-resistant

leukemia cell lines “,Cancer Chemother Pharmacol., 33,

1993,123.

107. Sivasubramanian Lakshmi., Mervin Arul, M., Jayasankar, L

Ramu, Indian. J.Pharm. Sci, 66, 2004,249.

108. Vadia NH, Patel VB, Indian J Pharm Sci, 68, 2006,584.

351

109. Budavari S.Eds, Merck Index,14th edition, Edited by Maryadele,

J.O.Neil, Merck Research lab, division of Merck & Co., NJ,

2006, monograph no.4902,4905.

110. Oostendorp RL, Beijnen JH, Schellens JH, Tellingen O,

“Determination of imatinib mesylate and its main metabolite

(CGP74588) in human plasma and murine specimens by ion-

pairing reversed-phase high-performance liquid

chromatography”, Biomed Chromatog, 21(7), 2007, 747-54.

112. Guetens G, Prenen H, Boeck G De, Oosterom A van,Schöffski P,

Highley M, Bruijn EA de,” Simultaneous determination of

AMN107 and Imatinib (Gleevec,Glivec,STI571) in cultured tumour

cells using an isocratic high-performance liquid chromatography

procedure with UV detection”, J Chromatogr B Analyt Technol

Biomed Life Sci,846(1-2), 2007,341-5.

113. Titier K, Picard S, Ducint D, ETeilhet , Moore N, Berthaud P,

Mahon FX, Molimard M,” Quantification of imatinib in human

plasma by high-performance liquid chromatography-tandem

mass spectrometry”,Ther Drug Monit,27(4), 2005,634-40.

114. Widmer N,Béguin A, Rochat B, Buclin T, Kovacsovics T,

Duchosal MA, Leyvraz S, Rosselet A, Biollaz J, Decosterd LA,”

Determination of imatinib (Gleevec) in human plasma by solid-

phase extraction-liquid chromatography-ultraviolet absorbance

352

detection”, J Chromatogr B Analyt Technol Biomed Life Sci,

803(2), 2004,285-92.

115. Ivanovic D, Medenica M, Jancic B,Malenovic A,” Reversed-

phase liquid chromatography analysis of imatinib mesylate and

impurity product in Glivec capsules”,J Chromatogr B Analyt

Technol Biomed Life Sci,800(1-2), 2004,253-8.

116. Bende G, Kollipara S, Sekar V, Saha R,"UV-spectrophotometric

determination of imatinib mesylate and its application in

solubility studies",Pharmazie,63(9),2008,641-5.

117. Martindale, The Complete Drug Reference, Edited by Sean C

Sweetman, 34th Edition, 2005, p.557.

118. Budavari S.Eds, Merck Index,14th edition, Edited by Maryadele,

J.O.Neil, Merck Research lab, division of Merck & Co., NJ,

2006, monograph no.4379,4377.

119. Puhringer-Oppermann FA, Stein HJ, Sarbia M, Dis

Esophagus, 20, 2007.

120. McKillop D, Partridge EA, Kemp JV, Spence MP, Kendrew J,

Barnett S,Guilbaud PG, Stephens TC,Mol Cancer Ther., 4,2005.

121. McKillop D, McCormick AD, Miles GS, Phillips PJ, Pickup KJ,

Bushby N, Hutchison M, Xenobiotica, 34, 2004.

122. Zhao M, Hartke C, Jimeno A, Li J, He P, Zabelina Y, Hidalgo M,

Baker SD, “Specific method for determination of gefitinib in

353

human plasma, mouse plasma and tissues using high

performance liquid chromatography coupled to tandem mass

spectrometry”, J Chromatogr B Analyt Technol Biomed Life Sci.,

819(1), 2005,73-80.

123. Jones HK, Stafford LE, Swaisland HC, Payne R, J Pharm

Biomed Anal., “A sensitive assay for ZD1839 (Iressa) in human

plasma by liquid-liquid extraction and high performance liquid

chromatography with mass spectrometric detection: validation

and use in Phase I clinical trials”, 29(1), 2002,221-8.

124. Budavari S.Eds, Merck Index,14th edition, Edited by Maryadele,

J.O.Neil, Merck Research lab, division of Merck & Co., NJ,

2006, monograph no.1754,1753.

125. Dhananjeyan MR, Liu J, Bykowski C, Trendel JA et.al, “Rapid

and simultaneous determination of capecitabine and its

metabolites in mouse plasma, mouse serum, and in rabbit bile

by high-performance liquid chromatography”, J Chromatogr A.,

1138(1-2), 2007, 101-8.

126. Guichard SM, Mayer I, Jodrell DI, J Chromatogr B Analyt

Technol Biomed Life Sci., 826, 2005,232.

127. Li KM, Rivory LP, Clarke SJ, J Chromatogr B Analyt Technol

Biomed Life Sci., 820, 2005,121.

354

128. Siethoff C, Orth M, Ortling A, Brendel E, Wagner-Redeker W,

“Simultaneous determination of capecitabine and its metabolite

5-fluorouracil by column switching and liquid

chromatographic/tandem mass spectrometry”, J Mass

Spectrom., 39(8), 2004,884-9.

129. Zufía L, Aldaz A, Giráldez J, “Simple determination of

capecitabine and its metabolites by liquid chromatography with

ultraviolet detection in a single injection”, J Chromatogr B

Analyt Technol Biomed Life Sci., 809(1), 2004, 51-8.

130. Xu Y, Grem JL, “Liquid chromatography-mass spectrometry

method for the analysis of the anti-cancer agent capecitabine

and its nucleoside metabolites in human plasma”, J

Chromatogr B Analyt Technol Biomed Life Sci., 783(1), 2003,

273-85.

132. Vanitha Prakash K, Venkateswara Rao J,Appala Raju

N,”Validated Reverse Phase HPLC method for the determination

of capecitabine in pharmaceutical dosage forms”, Oriental

Journal of Chemistry, 24, 2008,335.

133. Sethi P.D, High Performance Liquid Chromatography,

Quantitative Analysis of Pharmaceutical Formulations, CBS

Publishers & Distributors, 2001, 3.

355

134. Skoog D.A., Holler F.J., and Nieman, T.A., Principles of

Instrumental Analysis, 5th Edn, 1997.

135. Jansson, S.O., and. Johansson, S., J.Chromatogr. 1982, 242,

41.

136. Heftmann, E., Ed., Chromatography, 5th Ed., Elsevier,

Amsterdan, 1992.

137. Poole, C.F., and Poole S.K., Chromatography, Today Elsevier,

Amsterdan, 1991.

138. Grob, R.L., Ed., Modern practice of Gas Chromatography, 3rd

edn, Wiley-Interscience, New York, 1995.

139. Weinberger, R., Practical Capillary Electrophoresis, Academic

press, San Dioego. CA, 1993.

140. Kirchner, J.G., Thin-Layer Chromatography, 2nd Edn., Wiley-

Interscience, New York, 1978.

141. Lee, M.L., and Markides K.E., eds., Analytical Supercritical

Fluid Chromatography and Extraction Chromatography

Conferences, Inc., Provo. UT. 1990.

142. Small, H., Ion Chromatography, Plenum, New York, 1989.

143. Yau, W.W., Kirkland, J.J., and Bly, D.D., Modern Size-

Exclusion Liquid Chromatography, Wiley-Interscience, New

York 1979.

144. Braumann, T., Weber, G., and Grimme L.H., J. Chromatogr.,

1983, 261, 329.

145. Snyder, L.R., Dolan, J.W., and Rommen, D.C., J. Chromatogr.,

1989, 485, 91.

146. Dolan, J.W., Lommen, D.C., and Snyder, L.R., J.Chromatogr.,

1989, 485, 91.

356

147. Li, Z., Rutan, S.C., and Dong, S., Anal. Che., 1996, 68, 124.

148. Dolan, J.W., and Snyder, L.R., Trouble Shooting LC System,

Humana Press, Totowa, N.J., 1989.

149. USP 31/NF 26, Asian Edition, United States Pharmacopoeia

Convention, Volume 1, 2008,684.

150. Validation of Analytical Methods: Definitions and Terminology,

ICH Harmonised Tripartite Guideline, ICH Topic Q2A, 1994.

151. Validation of Analytical Procedures,Methodology, Step 4,

Consensus,ICH Harmonised Tripartite Guideline, ICH Q2 B.

1996.

152. Martindale, the Extra Pharmacopoeia, 31st Edition, Royal

Pharmaceutical Society, 1996, 604.

153. rd KE, Schaiquevich P, Bai F, Fraga CH, Miller L, Panetta JC,

Stewart CF, “Application of a highly specific and sensitive

fluorescent HPLC method for topotecan lactone in whole blood”,

23(7),707-13, 2009.

154. de Vries NA, Ouwehand M, Buckle T, Beijnen JH, van Tellingen

O,”Determination of topotecan in human and mouse plasma

and in mouse tissue homogenates by reversed-phase high-

performance liquid chromatography“,Biomed

Chromatogr.,21(11),2007,1191-200.

155. Gravel E, Bourget P, Mercier L, Paci A,"Fluorescence detection

combined with either HPLC or HPTLC for pharmaceutical

357

quality control in a hospital chemotherapy production unit:

application to camptothecin derivatives"J Pharm Biomed

Anal.,39(3-4),2005,581-6.

156. Vali AM, Shafaghi B, Dadashzadeh S,"Simple and sensitive high

performance liquid chromatographic method for the

simultaneous quantitation of the lactone and carboxylate forms

of topotecan in human plasma",J Chromatogr B Analyt Technol

Biomed Life Sci,818(2),2005,205-12.

157. Chen J, Balthasar JP,"High-performance liquid

chromatographic assay for the determination of total and free

topotecan in the presence and absence of anti-topotecan

antibodies in mouse plasma",J Chromatogr B Analyt Technol

Biomed Life Sci,816(1-2),2005,183-92.

158. Bai F, Kirstein MN, Hanna SK, Iacono LC, Johnston B, Stewart

CF,"Determination of plasma topotecan and its metabolite N-

desmethyl topotecan as both lactone and total form by reversed-

phase liquid chromatography with fluorescence detection",J

Chromatogr B Analyt Technol Biomed Life Sci,784(2),2003,225-

32.

159. Martindale, the Extra Pharmacopoeia, 31st Edition, Royal

Pharmaceutical Society, 1996, 544.

358

160. M, Rudek MA, He P, Hartke C, Gore S, Carducci MA, Baker

SD,"Quantification of 5-azacytidine in plasma by electrospray

tandem mass spectrometry coupled with high-performance

liquid chromatography",J Chromatogr B Analyt Technol Biomed

Life Sci,813(1-2),2004,81-8.

161. Liu Z, Marcucci G, Byrd JC, Grever M, Xiao J, Chan

KK,"Characterization of decomposition products and preclinical

and low dose clinical pharmacokinetics of decitabine (5-aza-2'-

deoxycytidine) by a new liquid chromatography/tandem mass

spectrometry quantification method",Rapid Commun Mass

Spectrom, 20(7), 2006, 1117-26.

162. Rustum AM, Hoffman NE,"High-performance liquid

chromatographic determination of 5-azacytidine in plasma", J

Chromatogr, 421(2), 1987, 387-91.

163. Lin KT, Momparler RL, Rivard GE, "Sample preparation for the

determination of 5-aza-2'-deoxycytidine in plasma by high

performance liquid chromatography", J Chromatogr, 345(1),

1985, 162-7.

164. Galushko SV, Shishkina IP, "Reversed-phase ion-paired high-

performance liquid chromatographic determination of 6-

azacytidine in blood", J Chromatogr, 345(1), 1985, 157-61.

359

165. McMaster, Marvin C. (2005). LC/MS: a practical user's guide.

New York: John Wiley. ISBN 0-471-65531-7.

166. Wilfried M.A. Niessen, Wilfried M. Niessen (2006). Liquid

Chromatography-Mass Spectrometry, Third Edition

(Chromatographic Science). Boca Raton: CRC. ISBN 0-8247-

4082-3.

167. ThurmanE.M,Ferrer,Imma(2003). Liquid chromatography/mass

spectrometry, MS/MS and time of flight MS: analysis of

emerging contaminants. Columbus, OH: American Chemical

Society. ISBN 0-8412-3825-1.

168. Ardrey, R. E.; Ardrey, Robert (2003). Liquid chromatography-

mass spectrometry: an introduction. London: J. Wiley. ISBN 0-

471-49801-7.

169. Yergey, Alfred L. (1990). Liquid chromatography/mass

spectrometry: techniques and applications. New York: Plenum

Press. ISBN 0-306-43186-6.

170. U.S .Department of Health and Human Services, Food and Drug

Administration., Guidance for Industry, Bioanalytical

Method Validation, May2001.

171. Nowatzke W, Woolf E, Best Practices during Bioanalytical

Method Validation for the Characterization of Assay Reagents

and the Evaluation of Analyte Stability in Assay Standards,

360

Quality Controls, and Study Samples, AAPS Journal. 9(2), 2007,

E117-E122.

172. Braggio S, Barnaby R.J, Grosi P , Cugola M, A strategy for

validation of bioanalytical methods,Journal of Pharmaceutical

and Biomedical Analysis 1996, 14, 375- 388.

173. Boulanger B. , Chiap P. Dewe W., Crommen J., Hubert Ph., An

analysis of the SFSTP guide on validation of chromatographic

bioanalytical methods: progresses and limitations Journal of

Pharmaceutical and Biomedical Analysis,32, 2003,753-765.

174. Causon Roger, Validation of chromatographic methods in

biomedical analysis viewpoint and discussion, Journal of

Chromatography B, 689 (1997) 175-180.

175. Hartmann C., Smeyers-Verbeke J., Massart D. L., McDowall

R.D., Validation of bioanalytical chromatographic methods,

Journal of Pharmaceutical and Biomedical Analysis17,

1998,193–218.

176. Kelley M, DeSilva, B.,Key Elements of Bioanalytical Method

Validation for Macromolecules., AAP Journal. 2007, 9(2), E156-

E163.

177. Albano J, Howell A. Robertson JFR, Quaresma. “Fulvestrant is

as effective as anastrozole in postmenopausal women with

361

advanced breast cancer progressing, after prior endocrine

treatment.” J. Clinical Oncology, 20, 2002, 3396-3403.

178. Brunner N Coopman P, Garcia M, “Anti-proliferative and anti-

estrogenic effectsof ICI 164,384 and ICI 182,780 in 4-OH-

tamoxifen-resistant Rabbit breast-cancercells.”,International

Journal of Cancer 56, 1994,295-300.

179. Gee J, Robertson J, Nicholson R., “The Pharmacokinetics of

single-dose FaslodexTM (ICI 182,780) in post-menopausal

primary breast cancer; relationship with estrogen receptor(ER)

down-regulation”, [abstract no.362]. Process American Society

Clinical Oncology, 19, 2000, 94A.

180. Howell A, Osborne CK, Morris C, Wakeling AE. ICI 182,780

(Faslodex): “Development of a novel, “pure” antiestrogen.”,

Cancer, 89, 2000, 817.

181. Jordan VC, Murphy CS.”Endocrine pharmacology of

antiestrogens as antitumor agents.” Endocr Rev., 11, 1990,578-

610.

182. Lykkesfeldt AE. “Mechanisms of tamodifen resistance in the

treatment of advanced breast cancer.”, Acta Oncology.,

35(Suppl-5), 1996, 9-14.

183. Robertson JR, Howell A. DeFeriend DJ. “Pharmacokinetics

pharmacological and anti-tumor effects of the specific anti-

362

oestrogen in women with advanced breast cancer.”, British

Journal of Cancer,74, 1996,300-308.

184. Shah VP, Midha KK, Dighe S, McGilveray IJ, Skelly JP and

Yacobi A et al. Analytical methods validation: bioavailability,

bioequivalence and pharmacokinetic studies Conference report,

European Journal of Drug Metabolism and Pharmacokinetics,

16, 1991,249.

185. Wakeling AE.,”The future of new pure antiestrogens in clinical

breast cancer. Breast Cancer Research and Treatment.” 25,

1993, 1-9.